Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)

被引：0
|
作者：
Gritsaev, S. [1 ]
Martinkevitch, I. [1 ]
Petrova, E. [1 ]
Kostroma, I. [1 ]
Ivanova, M. [1 ]
Sergeev, A. [1 ]
Tiranova, S. [1 ]
Potichonova, N. [1 ]
机构：
[1] Inst Hematol & Transfusiol, St Petersburg, Russia
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70192-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-144
引用
收藏
页码：S88 / S88
页数：1
相关论文
共 50 条
  • [21] Management of del(5q) MDS
    Giagounidis, A.
    LEUKEMIA RESEARCH, 2009, 33 : S27 - S27
  • [22] Role of lenalidomide in management of pure red cell aplasia (PRCA) and myelodysplastic syndromes (MDS) with del(5q)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A. M.
    LEUKEMIA RESEARCH, 2013, 37 : S100 - S100
  • [23] Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
    Almeida, Antonio
    Fenaux, Pierre
    List, Alan F.
    Raza, Azra
    Platzbecker, Uwe
    Santini, Valeria
    LEUKEMIA RESEARCH, 2017, 52 : 50 - 57
  • [24] Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing
    Haferlach, Claudia
    Bacher, Ulrike
    Tiu, Ramon
    Maciejewski, Jaroslaw P.
    List, Alan
    CANCER GENETICS AND CYTOGENETICS, 2008, 187 (02) : 101 - 111
  • [25] Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Capodanno, Isabella
    Neri, Antonino
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) : 860 - 869
  • [26] Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile
    Oelschlaegel, U.
    Westers, T. M.
    Mohr, B.
    Parmentier, S.
    Sockel, K.
    Bornhaeuser, M.
    Van de Loosdrecht, A. A.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2013, 37 : S47 - S48
  • [27] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [28] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
    Schuler, E.
    Schemenau, J.
    Giagounidis, A.
    Haase, D.
    Bueshce, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Luebbert, M.
    Schafhausen, P.
    Bug, G.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
  • [29] ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A.
    HAEMATOLOGICA, 2013, 98 : 691 - 692
  • [30] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
12345